# A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Source: https://onco.cc/trials/nct04078295/  
OnCo record `nct04078295` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Eisai Co., Ltd., active and no longer recruiting.

## Summary

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor is a phase 1/2 interventional study registered as NCT04078295 by Eisai Co., Ltd., with 125 participants enrolled, started 2019-09-05 and due to reach its primary completion in 2027-03-31. Interventions recorded: E7389-LF and Nivolumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04078295
- Phase: 1/2
- Setting: An Open-Label Phase 1b/2 Study of E7389 Liposomal Formulation Plus Nivolumab in Subjects With Solid Tumor
- Sponsor: Eisai Co., Ltd.
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT04078295: https://clinicaltrials.gov/study/NCT04078295

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Deciphera Pharmaceuticals (Ono)](https://onco.cc/companies/deciphera/), [Eisai](https://onco.cc/companies/eisai/)

---
JSON: https://onco.cc/api/v1/entities/nct04078295.json